## PENDING CLAIMS

9. A process for minimizing thermal aggregation of DNase in a liquid solution comprising introducing a DNase aggregation-inhibiting amount of sugar to a solution comprising DNase, and elevating the temperature of said DNase solution above 37°C temperature.

10. A process according to claim 9, wherein the temperature of said solution is elevated above about 60°C.

11. A process according to claim 9, further comprising reducing the pH of said solution below pH 7.0.

12. A process according to claim 11, wherein said solution is at about pH 6.5.

13. A process according to claim 11, wherein said solution is at about pH 6.

14. A process according to claim 11, wherein said solution is at about pH 5.

15. A process according to claim 9, wherein said sugar is present in an amount from 50 mg/ml to 200 mg/ml.

16. A process according to claim 9, wherein said sugar is α-lactose monohydrate, mannitol, trehalose or sucrose.

17. The process according to claim 9, further comprising the steps of spray-drying said liquid solution and collecting the spray-dried product as a respirable DNase-containing powder that is therapeutically effective when administered into the lung of an individual.

18. A DNase solution comprising DNase and a DNase aggregation-inhibiting amount of sugar wherein said DNase solution is minimally aggregated when said solution is at a temperature greater than 37°C.

19. A DNase solution according to claim 18, wherein the temperature is greater than about 60°C.

20. A DNase solution according to claim 18, wherein said solution is further kept at a pH below 7.0.

21. A DNase solution according to claim 20, wherein said solution is at about pH 6.5.

22. A DNase solution according to claim 20, wherein said solution is at about pH 6.

23. A DNase solution according to claim 18, wherein said sugar is present in an amount from 50 mg/ml to 200 mg/ml.

24. A DNase solution according to claim 18, wherein said sugar is α-lactose monohydrate, mannitol, trehalose or sucrose.

25. A DNase solution according to claim 18 that is further spray-dried to a respirable DNase-containing powder that is therapeutically effective when administered into the lung of an individual.